⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MXCT News
MaxCyte, Inc. Common Stock
MaxCyte to Participate in Three Upcoming Investor Conferences
globenewswire.com
MXCT
Form 8-K
sec.gov
MXCT
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
globenewswire.com
MXCT
North America Non-Viral Transfection Reagents Market Forecast to 2035 | Cell and Gene Therapy Demand Drives 8.5% CAGR and a USD 0.70 Billion Opportunity
globenewswire.com
TMO
MXCT
BIO
HBIO
RIVN
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
globenewswire.com
MXCT
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
MXCT
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
globenewswire.com
MXCT
Form 8-K
sec.gov
MXCT
MaxCyte Reports Second Quarter 2026 Financial Results
globenewswire.com
MXCT
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
globenewswire.com
MXCT